UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Structural basis of inhibition of the human SGLT2–MAP17 glucose transporter

Nature (London), 2022-01, Vol.601 (7892), p.280-284

2022

Volltextzugriff (PDF)

Biocomputational Prediction Approach Targeting FimH by Natural SGLT2 Inhibitors: A Possible Way to Overcome the Uropathogenic Effect of SGLT2 Inhibitor Drugs

Molecules (Basel, Switzerland), 2021-01, Vol.26 (3), p.582

2021

Volltextzugriff (PDF)

Uncovering the antidiabetic potential of heart-friendly and diuretic bioactive compounds through computer-based drug design

Computational biology and chemistry, 2024-10, Vol.112, p.108180, Article 108180

2024

Volltextzugriff (PDF)

Concise and Stereodivergent Synthesis of Carbasugars Reveals Unexpected Structure-Activity Relationship (SAR) of SGLT2 Inhibition

Scientific reports, 2017-07, Vol.7 (1), p.5581-8, Article 5581

2017

Volltextzugriff (PDF)

Structural selectivity of human SGLT inhibitors

American Journal of Physiology: Cell Physiology, 2012-01, Vol.302 (2), p.C373-C382

2012

Volltextzugriff (PDF)

Molecular docking and dynamics simulation of Orthosiphon stamineus against SGLT1 and SGLT2

Journal of biomolecular structure & dynamics, 2023, Vol.41 (23), p.13663-13678

2023

Volltextzugriff (PDF)

Effects of SGLT2 inhibitors on fractures and bone mineral density in type 2 diabetes: An updated meta‐analysis

Diabetes/metabolism research and reviews, 2019-10, Vol.35 (7), p.e3170-n/a

2019

Volltextzugriff (PDF)

Do sodium‐glucose co‐transporter‐2 inhibitors prevent heart failure with a preserved ejection fraction by counterbalancing the effects of leptin? A novel hypothesis

Diabetes, obesity & metabolism, 2018-06, Vol.20 (6), p.1361-1366

Packer, Milton

2018

Volltextzugriff (PDF)

Simple, fast and robust LC-MS/MS method for the simultaneous quantification of canagliflozin, dapagliflozin and empagliflozin in human plasma and urine

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2020-09, Vol.1152, p.122257, Article 122257

2020

Volltextzugriff (PDF)

Marein ameliorates diabetic nephropathy by inhibiting renal sodium glucose transporter 2 and activating the AMPK signaling pathway in db/db mice and high glucose–treated HK-2 cells

Biomedicine & pharmacotherapy, 2020-11, Vol.131, p.110684, Article 110684

2020

Volltextzugriff (PDF)

Ipragliflozin improves mitochondrial abnormalities in renal tubules induced by a high‐fat diet

Journal of diabetes investigation, 2018-09, Vol.9 (5), p.1025-1032

2018

Volltextzugriff (PDF)

Molecular Interaction of Anti‐Diabetic Drugs With Acetylcholinesterase and Sodium Glucose Co‐Transporter 2

Journal of cellular biochemistry, 2017-11, Vol.118 (11), p.3855-3865

Shakil, Shazi

2017

Volltextzugriff (PDF)

Synthetic strategy and SAR studies of C-glucoside heteroaryls as SGLT2 inhibitor: A review

European journal of medicinal chemistry, 2019-12, Vol.184, p.111773-111773, Article 111773

2019

Volltextzugriff (PDF)

Ultrasound-assisted dispersive liquid–liquid microextraction for determination of three gliflozins in human plasma by HPLC/DAD

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2020-01, Vol.1136, p.121932-121932, Article 121932

2020

Volltextzugriff (PDF)

Discovery of GCC5694A: A potent and selective sodium glucose co-transporter 2 inhibitor for the treatment of type 2 diabetes

Bioorganic & medicinal chemistry letters, 2022-01, Vol.56, p.128466-128466, Article 128466

2022

Volltextzugriff (PDF)

Clinical implications of current cardiovascular outcome trials with sodium glucose cotransporter-2 (SGLT2) inhibitors

Atherosclerosis, 2018-05, Vol.272, p.33-40

2018

Volltextzugriff (PDF)

Development of a Scalable Synthesis of Tofogliflozin

Journal of organic chemistry, 2016-03, Vol.81 (5), p.2148-2153

2016

Volltextzugriff (PDF)

Trilobatin, a Novel SGLT1/2 Inhibitor, Selectively Induces the Proliferation of Human Hepatoblastoma Cells

Molecules (Basel, Switzerland), 2019-09, Vol.24 (18), p.3390

2019

Volltextzugriff (PDF)

Design, synthesis and biological evaluation of 6-deoxy O-spiroketal C-arylglucosides as novel renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes

European journal of medicinal chemistry, 2019-10, Vol.180, p.398-416

2019

Volltextzugriff (PDF)

Discovery of a potent, low-absorbable sodium-dependent glucose cotransporter 1 (SGLT1) inhibitor (TP0438836) for the treatment of type 2 diabetes

Bioorganic & medicinal chemistry letters, 2018-12, Vol.28 (22), p.3534-3539

2018

Volltextzugriff (PDF)

In-silico screening and identification of phytochemicals from Centella asiatica as potential inhibitors of sodium-glucose co-transporter 2 for treating diabetes

Journal of biomolecular structure & dynamics, 2022-01, Vol.40 (22), p.12221-12238

2022

Volltextzugriff (PDF)

SGLT2 inhibitors: further evidence for heart failure with preserved ejection fraction as a metabolic disease?

The Journal of clinical investigation, 2021-12, Vol.131 (23)

2021

Volltextzugriff (PDF)

Design, synthesis and biological evaluation of (2S,3R,4R,5S,6R)-5-fluoro-6-(hydroxymethyl)-2-aryltetrahydro-2H-pyran-3,4-diols as potent and orally active SGLT dual inhibitors

Bioorganic & medicinal chemistry letters, 2018-11, Vol.28 (21), p.3446-3453

2018

Volltextzugriff (PDF)

New Diabetes Therapies and Diabetic Kidney Disease Progression: the Role of SGLT-2 Inhibitors

Current diabetes reports, 2018-05, Vol.18 (5), p.27-12, Article 27

2018

Volltextzugriff (PDF)

Novel frame-shift mutation in Slc5a2 encoding SGLT2 in a strain of senescence-accelerated mouse SAMP10

Biochemical and biophysical research communications, 2014-11, Vol.454 (1), p.89-94

2014

Volltextzugriff (PDF)

1 – 25 von 601

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(592)
Mit Volltextzugriff
(512)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(569)
Life Sciences & Biomedicine
(545)
Humans
(429)
Animals
(308)
Biochemistry & Molecular Biology
(299)
Glucose
(233)
Diabetes
(217)
Chemistry
(210)
Physical Sciences
(210)
Pharmacology & Pharmacy
(205)
Diabetes Mellitus, Type 2 - Drug Therapy
(203)
Diabetes Mellitus
(176)
Male
(155)
Sodium-Glucose Transporter 2 - Metabolism
(151)
Sodium-Glucose Transporter 2 Inhibitors - Pharmacology
(140)
Chemistry, Multidisciplinary
(138)
Chemistry, Medicinal
(134)
Hypoglycemic Agents - Pharmacology
(128)
Sodium-Glucose Transporter 2 - Antagonists & Inhibitors
(120)
Sodium-Glucose Transporter 2 Inhibitors - Therapeutic Use
(117)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(8)

Menü

Weitere Dienste

Einstellungen

Structural basis of inhibition of the human SGLT2–MAP17 glucose transporter

Biocomputational Prediction Approach Targeting FimH by Natural SGLT2 Inhibitors: A Possible Way to Overcome the Uropathogenic Effect of SGLT2 Inhibitor Drugs

Uncovering the antidiabetic potential of heart-friendly and diuretic bioactive compounds through computer-based drug design

Concise and Stereodivergent Synthesis of Carbasugars Reveals Unexpected Structure-Activity Relationship (SAR) of SGLT2 Inhibition

Structural selectivity of human SGLT inhibitors

Molecular docking and dynamics simulation of Orthosiphon stamineus against SGLT1 and SGLT2

Effects of SGLT2 inhibitors on fractures and bone mineral density in type 2 diabetes: An updated meta‐analysis

Do sodium‐glucose co‐transporter‐2 inhibitors prevent heart failure with a preserved ejection fraction by counterbalancing the effects of leptin? A novel hypothesis

Simple, fast and robust LC-MS/MS method for the simultaneous quantification of canagliflozin, dapagliflozin and empagliflozin in human plasma and urine

Marein ameliorates diabetic nephropathy by inhibiting renal sodium glucose transporter 2 and activating the AMPK signaling pathway in db/db mice and high glucose–treated HK-2 cells

Ipragliflozin improves mitochondrial abnormalities in renal tubules induced by a high‐fat diet

Molecular Interaction of Anti‐Diabetic Drugs With Acetylcholinesterase and Sodium Glucose Co‐Transporter 2

Synthetic strategy and SAR studies of C-glucoside heteroaryls as SGLT2 inhibitor: A review

Ultrasound-assisted dispersive liquid–liquid microextraction for determination of three gliflozins in human plasma by HPLC/DAD

Discovery of GCC5694A: A potent and selective sodium glucose co-transporter 2 inhibitor for the treatment of type 2 diabetes

Clinical implications of current cardiovascular outcome trials with sodium glucose cotransporter-2 (SGLT2) inhibitors

Development of a Scalable Synthesis of Tofogliflozin

Trilobatin, a Novel SGLT1/2 Inhibitor, Selectively Induces the Proliferation of Human Hepatoblastoma Cells

Design, synthesis and biological evaluation of 6-deoxy O-spiroketal C-arylglucosides as novel renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes

Discovery of a potent, low-absorbable sodium-dependent glucose cotransporter 1 (SGLT1) inhibitor (TP0438836) for the treatment of type 2 diabetes

In-silico screening and identification of phytochemicals from Centella asiatica as potential inhibitors of sodium-glucose co-transporter 2 for treating diabetes

SGLT2 inhibitors: further evidence for heart failure with preserved ejection fraction as a metabolic disease?

Design, synthesis and biological evaluation of (2S,3R,4R,5S,6R)-5-fluoro-6-(hydroxymethyl)-2-aryltetrahydro-2H-pyran-3,4-diols as potent and orally active SGLT dual inhibitors

New Diabetes Therapies and Diabetic Kidney Disease Progression: the Role of SGLT-2 Inhibitors

Novel frame-shift mutation in Slc5a2 encoding SGLT2 in a strain of senescence-accelerated mouse SAMP10

Suchergebnisse filtern